Organon Q2 2023 revenue $1.61B (+4% ex-FX); adj. EPS $1.31; FY guidance narrowed

Organon & Co.

2023-Q2 EPS reported $1.64 revenue$3,146,000,000

GAAP diluted EPS $0.95; non-GAAP adjusted diluted EPS $1.31 vs $1.25 prior year.
Women's Health revenue $438M (+10% ex-FX); Nexplanon up 12% ex-FX; fertility +17% ex-FX.
Biosimilars $135M (+15% ex-FX); Renflexis +20% ex-FX; Hadlima launched in US July 1.
Established Brands $995M (flat ex-FX); expects flat full-year revenue.
FY 2023 revenue guidance narrowed to $6.25-6.45B; adj. EBITDA margin 31.5%-33.0%.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Organon & Co. reported the second quarter ended June 30, 2023 results: revenue $1,608 million, net income $242 million, EPS $0.95. Guidance reaffirmed.

Period: the second quarter ended June 30, 2023
Revenue: $1,608 million
Net income: $242 million
EPS: $0.95
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Organon Reports Results for the Second Quarter Ended June 30, 2023 • Second quarter 2023 revenue of $1,608 million • Second quarter 2023 diluted earnings per share of $0.95

View on SEC.gov

Browse all earnings releases →

Organon & Co. filing history →

Source: SEC EDGAR

accession 0001104659-23-088621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.